GLP-1 Hair Loss: Why Ozempic, Wegovy, Mounjaro, and Zepbound Cause Shedding, and What Actually Helps
You did everything right. You talked to your doctor, you started the medication, the weight started coming off, and your labs began moving in the direction they were supposed to. And then, somewhere around month three or four, you noticed the drain.
Not a few strands. A tangle. Then more on the pillow, more in the brush, more collecting at your part every time you looked in the mirror under bad lighting. And when you mentioned it, someone (maybe a prescriber, maybe a friend, maybe the internet) told you it was probably nothing. Just stress. Just normal shedding. Just what happens.
It isn't nothing. And you're not imagining it.
First: this is a real, documented effect, not a rumor
For a couple of years, GLP-1-related hair shedding lived mostly in Reddit threads and TikTok comments, which made it easy to dismiss. That's no longer where the evidence sits.
In May 2026, researchers at West Virginia University published the largest analysis of this question to date in Archives of Dermatological Research.1 Using a database of more than 400,000 propensity-matched patients, they compared people starting a GLP-1 with people starting metformin, adjusting for age, sex, obesity, diabetes, smoking, thyroid disease, PCOS, lupus, and pregnancy.
The findings were specific rather than sweeping:
| Medication | Relative risk of new nonscarring hair loss | Significant? |
|---|---|---|
| Semaglutide (Ozempic, Wegovy) | 1.43 (95% CI 1.30 to 1.56) | Yes |
| Tirzepatide (Mounjaro, Zepbound) | 1.68 (95% CI 1.44 to 1.97) | Yes |
| Liraglutide | 1.12 (95% CI 0.93 to 1.37) | No |
| Dulaglutide | 0.94 (95% CI 0.77 to 1.14) | No |
In plain terms: people starting semaglutide were diagnosed with nonscarring hair loss about 43% more often than matched patients on metformin, and people starting tirzepatide about 68% more often.1
Your medication is working, your hair is responding, and both of those things can be true at once. The goal is not to choose between them.
Notice which drugs top that list. The two with a significant signal are also the two that produce the most weight loss. The study authors point to this pattern as the key clue: it suggests the shedding is driven by the weight loss itself rather than by the drug damaging the follicle.1 That distinction matters enormously for what you do next, because a follicle that is resting is a follicle that can be woken up.
This was an observational study, which means it shows an association, not proof of cause. The researchers were not able to measure how much weight each patient actually lost, so the weight-loss explanation is a well-supported hypothesis rather than a proven mechanism. The study also grouped several different types of hair loss together and did not track how long shedding lasted or whether it resolved. Absolute rates stayed low: roughly 0.6% of semaglutide patients received a hair loss diagnosis within a year, versus about 0.45% on metformin.1 A higher relative risk on a small baseline is still a small individual risk.
What's actually happening inside your scalp
Your hair grows in a cycle. Most of your follicles, normally around 85 to 90%, sit in anagen, the active growing phase, which can last years. A small percentage are in catagen (a brief transitional shutdown) and telogen (a resting phase of roughly three months), at the end of which the old hair releases and a new one begins pushing up behind it.
Telogen effluvium is what happens when a physiological stressor pushes an abnormally large share of your follicles out of anagen and into telogen all at the same time. They then all release at once, roughly two to four months later. That delay is why the shedding so often feels like it comes out of nowhere. The trigger happened last season, not last week.
Rapid weight loss is a well-established trigger. Here's how a GLP-1 can create several of them simultaneously:
1. Caloric and metabolic shock
Your body reads a fast, substantial energy deficit as a threat and reallocates resources toward organs that keep you alive. Hair, being biologically expendable, is among the first systems downregulated. This isn't a malfunction. It's triage.
2. Genuine nutrient gaps
GLP-1s work substantially by suppressing appetite, which means many people are eating meaningfully less food, not just fewer calories. Hair is a protein structure with high metabolic demand, and it's sensitive to shortfalls in protein, iron (measured as ferritin), zinc, vitamin D, and B12. Reviews of this literature specifically flag altered dietary intake and nutritional shortfall as likely contributors.2 If you're eating 900 calories a day because nothing sounds appealing, your follicles will find out before your bloodwork does.
3. Hormonal and growth-factor shifts
Changes involving insulin and insulin-like growth factor signaling, along with the ordinary stress of managing a chronic condition, may influence androgen activity and the follicle cycle, potentially setting off either telogen effluvium or androgenetic alopecia.2 This is the piece most articles skip, and it's the one that changes prognosis.
4. The unmasking effect
This is the important one. If you carry a genetic predisposition to pattern hair loss, you may have had it quietly progressing for years, hidden underneath density you didn't know you were relying on. A telogen effluvium event strips away that buffer. The shedding is temporary, but what it reveals underneath may not be. Many people who "lost their hair on Ozempic" actually lost their camouflage.
Which is exactly why a diagnosis matters more than a supplement.
Is this you? A quick self-check
You are more likely to be dealing with GLP-1-associated shedding, as opposed to something else entirely, if several of these apply:
- Shedding began roughly 2 to 4 months after starting or increasing your dose
- You're losing more than about 100 hairs a day, or noticeably more than your normal
- The loss feels diffuse, all over, rather than concentrated in one patch
- Your part looks wider, or your ponytail circumference has visibly shrunk
- You've lost weight quickly, or you're eating substantially less than you used to
- You're on semaglutide or tirzepatide specifically, at an obesity-treatment dose
- Shedding that continues past six months
- Thinning concentrated at the crown or part line, a pattern-loss signature
- Scalp itching, burning, tenderness, or visible scaling
- Distinct round or patchy bald areas
- Hair that isn't coming back after your weight has stabilized
What actually helps, staged by where you are
There is no single answer here, because there is no single cause. What follows is roughly the order we work through it at Transitions of Indiana.
Get a real diagnosis before you buy anything
This is the step almost everyone skips, and it's the one that saves the most time and money. A scalp and hair analysis with a certified trichologist uses magnified scalp imaging to look at what your follicles are actually doing: density, miniaturization, inflammation, sebum load, and the ratio of growing to resting hairs. That's how we distinguish "this will resolve" from "this has been progressing for six years and the medication just revealed it," which are two completely different treatment paths.
It's also how we know whether to send you back to your primary care provider for labs. Ferritin, TSH and thyroid panel, vitamin D, zinc, and B12 are the standard starting set for diffuse shedding, and they're worth asking for directly.
Book a scalp analysis"Can we check ferritin, not just hemoglobin, since I can have depleted iron stores with normal hemoglobin? Along with a full thyroid panel, vitamin D, zinc, and B12."
If you're told your labs are "normal," ask for the actual numbers. "Within range" and "optimal for hair growth" are not the same range.
Feed the follicle
Protein first. Most people on GLP-1s are under-eating protein without realizing it. A common clinical target is roughly 0.6 to 0.8 grams per pound of goal body weight, but ask your prescriber what's appropriate for you. Prioritize protein at every meal even when appetite is low, and consider whether a registered dietitian should be part of your care team. Many GLP-1 prescribing programs don't include one, and it shows.
A note on biotin, because it's everywhere: biotin supplementation reliably helps only people who are actually biotin-deficient, which is rare. More importantly, high-dose biotin can interfere with common lab assays, including thyroid tests and cardiac troponin, producing misleading results. If you take it, tell whoever draws your blood. Correcting a documented deficiency is worth doing. Taking megadoses on the assumption of one usually isn't.
Extend and support the growth phase
Once we know what we're treating, several evidence-supported options work well for shedding driven by metabolic stress:
- Low-level laser therapy (LLLT), an FDA-cleared, non-invasive light therapy that increases microcirculation at the follicle and supports the growth phase. Particularly well suited to early, diffuse thinning.
- CRLabs trichology protocols, pharmaceutical-grade topical and scalp-health regimens matched to what your analysis found, rather than to what's on the shelf at the drugstore.
- Topical minoxidil, still a first-line, well-studied option for extending anagen. Worth discussing with your provider, including the caveat that stopping it later means losing what it gained. If you're ready to start, we carry a 5% topical minoxidil treatment through We Grow Hair USA.
Regenerative and advanced therapies
For people whose shedding is prolonged, whose density hasn't recovered, or whose underlying pattern loss has been revealed, we go further:
- Enhanced plasma therapy, using concentrated growth factors from your own blood to stimulate follicles that have slowed down. Platelet-rich plasma is used clinically to support regrowth when recovery has stalled, though the evidence base is still building and large randomized trials are needed.
- DE|RIVE exosome treatment and extracellular vesicle therapies, among the most actively researched frontiers in hair regeneration, delivering signaling molecules directly into the follicular environment.
When the loss is permanent
If your weight has stabilized and the density hasn't returned, that's information, not failure. It usually means genetic pattern loss was underneath all along.
Non-surgical hair replacement delivers immediate, natural-looking density without a procedure, and modern systems are nothing like what the phrase used to mean. Female hair transplants and male hair transplants relocate follicles that are genetically resistant to loss into thinning areas, for a permanent structural solution.
Not sure what the results actually look like? Our women's gallery and men's gallery are real clients, real timelines.
Questions we hear every week
Take the next step, wherever you are
- Still figuring out what's happening? Book a free, private hair and scalp analysis. We'll tell you what we see, including if the answer is "wait, this will resolve on its own."
- Want to see what's possible first? Browse real client results
- Prefer to read more before you talk to anyone? Request our free hair loss information guide
- Ready to talk numbers? See low monthly payment options
You're allowed to want your health and your hair.
Transitions of Indiana has spent more than 25 years helping people in Indianapolis and across the country understand what's happening with their hair, and what can be done about it.
- Lanehart MH, Zinn Z, Beatty CJ. Association between GLP-1 receptor agonists and nonscarring hair loss: a population-based, propensity score matched cohort analysis. Archives of Dermatological Research. 2026;318:164. doi:10.1007/s00403-026-04603-w
- Desai DD, Sikora M, Nohria A, et al. GLP-1 agonists and hair loss: a call for further investigation. International Journal of Dermatology. 2024;63(9):1128-1130. doi:10.1111/ijd.17246
- Burke O, Sa B, Cespedes DA, Sechi A, Tosti A. Glucagon-like peptide-1 receptor agonist medications and hair loss: a retrospective cohort study. Journal of the American Academy of Dermatology. 2025;92(5):1141-1143. doi:10.1016/j.jaad.2025.01.046
- Godfrey H, Leibovit-Reiben Z, Jedlowski P, Thiede R. Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) from 2022 to 2023. Journal of the European Academy of Dermatology and Venereology. 2025;39(2):e153-e154. doi:10.1111/jdv.20197
